Proteomics and Metabolomics in Psychiatry

Description

This publication compiles data generated by proteomics and metabolomics about psychiatric disorders. Leading researchers in these fields review the basic principles of proteomics and metabolomics and propose the new directions to be followed in molecular psychiatry. The chapters divided into two sections – Schizophrenia/Psychotic Disorders and Mood Disorders – deal with findings in diverse tissues from human and preclinical models in order to unravel the biology and biochemistry behind the establishment and course of these illnesses as well as potential biomarkers for clinical applications. More than an update, this publication indicates the next steps to discover biomarkers and understand psychiatric disorders more comprehensively. This publication is valuable reading for psychiatrists, neuroscientists and analytical chemists interested in the basics of proteomics and metabolomics, psychiatric definitions and the most advanced hypotheses about the pathobiology of schizophrenia, depression and bipolar disorder.

Informations

• Publié par: S. Karger AG
• Date de parution: 23 mai 2014
• Nombre de lectures: 0
• EAN13: 9783318026009
• Langue: English
• Poids de l'ouvrage: 2 Mo

Extrait

Proteomics and Metabolomics in Psychiatry
Advances in Biological Psychiatry
Vol. 29
Series Editors
W.P. Kaschka Ravensburg
W.F. Gattaz São Paulo
Proteomics and Metabolomics in Psychiatry
Volume Editor
Daniel Martins-de-Souza Campinas/Munich
9 figures, 1 in color, and 10 tables, 2014
Advances in Biological Psychiatry
_______________________ Prof. Dr. Daniel Martins-de-Souza Laboratory of Neuroproteomics Department of Biochemistry, Institute of Biology University of Campinas (UNICAMP) Rua Monteiro Lobato, 255 13083-862 Campinas (Brazil) and Department of Psychiatry and Psychotherapy Ludwig Maximilian University of Munich (LMU) Nussbaumstrasse 7 DE–80336 Munich (Germany)
Library of Congress Cataloging-in-Publication Data
Proteomics and metabolomics in psychiatry / volume editor, Daniel Martins-de-Souza.
p. ; cm. -- (Advances in biological psychiatry, ISSN 0378-7354 ; Vol. 29)
Includes bibliographical references and index.
ISBN 978-3-318-02599-6 (hard cover: alk. paper) -- ISBN 978-3-318-02600-9 (e-ISBN)
I. Martins-de-Souza, Daniel, editor. II. Series: Advances in biological psychiatry ; v. 29. 0378-7354
[DNLM: 1. Mental Disorders--etiology. 2. Biological Markers. 3. Mental Disorders--diagnosis. 4. Mental Disorders--physiopathology. 5. Metabolomics--methods. 6. Proteomics--methods. W1 AD44 v.29 2014 / WM 140]
RC341
616.89--dc23
2014014405
Bibliographic Indices. This publication is listed in bibliographic services, including Current Contents ® and Index Medicus.
Disclaimer. The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the book is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Drug Dosage. The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
© Copyright 2014 by S. Karger AG, P.O. Box, CH–4009 Basel (Switzerland)
www.karger.com
Printed in Germany on acid-free and non-aging paper (ISO9706) by Kraft Druck, Ettlingen
ISSN 0378–7354
e-ISSN 1662–2774
ISBN 978–3–318–02599–6
e-ISBN 978–3–318–02600–9
Contents
Preface
Martins-de-Souza, D. (Campinas/Munich)
Schizophrenia and Psychotic Disorders
Proteomic Characterization of the Brain and Cerebrospinal Fluid of Schizophrenia Patients
Café-Mendes, C.C. (São Paulo/Munich); Gattaz, W.F. (São Paulo); Schmitt, A. (São Paulo/Munich); Britto, L.R.G. (São Paulo); Martins-de-Souza, D. (São Paulo/Campinas/Munich)
Peripheral Biomarker Candidates in Schizophrenia
Thome, J. (Rostock); Bratek, A.; Krysta, K. (Katowice)
Schizophrenia: Blood-Serum-Plasma Metabolomics
Lista, S.; Giegling, I.; Rujescu, D. (Halle)
Proteomic and Metabolomic Evidence for Glial Alterations in Schizophrenia
Beasley, C.L. (Vancouver, B.C.); Barakauskas, V.E. (Edmonton, Alta.)
Insights from Proteomic Studies on Schizophrenia Preclinical Models: What Can We Learn for Drug Discovery?
Farrelly, L.A.; Föcking, M.; Cotter, D.R. (Dublin)
Metabolomics to Study Psychotic Disorders and Their Metabolic Comorbidities
Orešič, M. (Espoo)
Mood Disorders
Peripheral Biomarkers for Depression by Plasma and Serum Proteomics
Domenici, E. (Basel)
Proteomics of Preclinical Models of Depression
Carboni, L. (Bologna)
Antidepressant Response Metabonomics
Qin, X.; Gao, X.; Qiao, Y.; Zhou, Y.; Tian, J.; Li, Z. (Taiyuan)
Proteomics and Metabolomics of Bipolar Disorder
Sussulini, A. (Campinas/Göttingen)
Use of Metabolomics and Proteomics to Reveal Pathophysiological Pathways in Anxiety Disorders
Altmaier, E.; Emeny, R.T. (Neuherberg)
Author Index
Subject Index
Preface
Psychiatric disorders are problems of immense importance for public health, ranging from patients’ welfare to health treatment systems. According to the World Health Organization ( http://www.who.int ), mental disorders compose 40% of the leading causes of disability in developed countries. In most of the cases there is a long delay between disease onset and clinical intervention, which can compromise treatment, leading to more severe illness. Psychiatric disorders are still neglected compared with other major health problems; it has been estimated, for instance, that in the USA proper management of depression can cost as much as that of heart diseases. Thus, in order to improve prognosis, diagnostics and current treatments, there is an urgent need to understand the molecular and biochemical bases of these disorders. These questions are still open, despite all scientific efforts.
Decipherment of the human genome pushed the development of other large-scale technologies for investigating the molecular bases of life. Proteomics and metabolomics are two of these technologies which can identify the protein and metabolite contents of a given cell, tissue or organism in a large-scale and high-throughput manner. In the case of psychiatric disorders, these technologies have been delineating a comprehensive characterization of the molecular mechanisms involved in the establishment and course of these illnesses. Moreover, proteomics and metabolomics have been unraveling biomarker candidates for prognosis, diagnosis, treatment and patient stratification.
This edition of Advances in Biological Psychiatry presents – apart from the basic principles of proteomics and metabolomics – all data generated by these technologies pertaining to a characterization of human samples from psychiatric patients as well as preclinical models. Eleven leading researchers in the field of schizophrenia and psychosis as well as in mood disorders contributed to this edition, reviewing the most important data generated by proteomics and metabolomics in the last decade. More than an update, this edition, entitled Proteomics and Metabolomics in Psychiatry , indicates the next steps to be followed in the search for biomarkers and a deeper understanding of psychiatric disorders.

Daniel Martins-de-Souza , Campinas/Munich
Schizophrenia and Psychotic Disorders
Martins-de-Souza D (ed): Proteomics and Metabolomics in Psychiatry. Adv Biol Psychiatry. Basel, Karger, 2014, vol 29, pp 1-15 (DOI: 10.1159/000358021)
______________________
Proteomic Characterization of the Brain and Cerebrospinal Fluid of Schizophrenia Patients
Cecília C. Café-Mendes a , c Wagner F. Gattaz b Andrea Schmitt b , d Luiz R.G. Britto a Daniel Martins-de-Souza b - e
a Department of Physiology and Biophysics, Institute of Biomedical Sciences and b Laboratory of Neurosciences (LIM-27), Institute of Psychiatry, University of São Paulo, São Paulo, Brazil; c Max Planck Institute of Psychiatry, and d Department of Psychiatry and Psychotherapy, Ludwig Maximilian University of Munich, Munich, Germany; e Laboratory of Neuroproteomics, Department of Biochemistry, Institute of Biology University of Campinas (UNICAMP), Campinas, Brazil
______________________
Abstract
As a multifactorial mental disorder, schizophrenia presents a complex combination of genetic, neurodevelopmental and environmental components. These lead to difficulties in comprehending the molecular basis of schizophrenia as well as in identifying biomarkers. These issues can be tackled by proteomics, which has been used increasingly along with genetics and other ‘-omics’ approaches. In the present chapter, we explore some advances in proteomic studies involving brain tissue and cerebrospinal fluid collected from schizophrenic patients. We demonstrate that proteomic findings have been confirmed by other approaches, and added new information about the role of synaptic connectivity, oxidative stress, glucose metabolism and cytoskeletal alterations as core features of the disease pathophysiology. Integrative systems analysis including proteomics is a valid strategy for understanding the molecular basis of schizophrenia and may indicate the way to future clinical applications.
© 2014 S. Karger AG, Basel
Schizophrenia
Schizophrenia is a severe mental disorder with a lifetime prevalence of 0.3–0.7% and presenting a heterogeneous range of symptoms [ 1 ] . It is a multifactorial disorder composed of a number of etiological factors of small effect that may be triggered by environmental components [ 2 ]. The causes of schizophrenia are strongly determined by genetics, but also by other factors such as epistatic (interaction between two or more genes controlling a single